Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/07/15 08:16:17」(JST)

wiki en

Iodixanol is a contrast agent, sold under the trade name Visipaque. Visipaque is commonly used as a contrast agent during coronary angiography. It is the only iso-osmolar contrast agent, with an osmolality of 290 mOsm/kg H₂O, the same as blood. It is sold in 2 main concentrations 270 mgI/ml and 320 mgI/ml - hence the name Visipaque 270 or 320. It is sold in single dose units and a large 500ml plastic bottle for multi-dose dispensing

It was originally made by Nycomed, which then merged with Amersham which finally was bought by Jeff Immelt to become GE Healthcare. The majority of Visipaque is made in Cork, Ireland, with additional plants in China and Oslo. All Iodixanol bulk powder is made in Norway and shipped to the various plants for final manufacture.

For density gradient centrifugation, the product is known as OptiPrep.

A very similar product also manufactured by GE Healthcare is Omnipaque (Iohexol as the main drug substance).

External links

http://www.amershamhealth-us.com/visipaque/
http://www.gehealthcare.com/caen/md/docs/visipaquepieng.pdf
Iodixanol drug label/data at Daily Med from U.S. National Library of Medicine, National Institutes of Health.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 造影剤誘発性腎症の予防 prevention of contrast induced nephropathy
2. 造影剤に対する即時型過敏反応：再発反応の予防 immediate hypersensitivity reactions to radiocontrast media prevention of recurrent reactions
3. 造影剤に対する即時型過敏反応：臨床症状、診断、および治療 immediate hypersensitivity reactions to radiocontrast media clinical manifestations diagnosis and treatment
4. 小児における急性虫垂炎：画像診断 acute appendicitis in children diagnostic imaging
5. 造影剤誘発性腎症の病因、臨床的特徴、および診断 pathogenesis clinical features and diagnosis of contrast induced nephropathy

English Journal

The Conserved Set of Host Proteins Incorporated into HIV-1 Virions Suggests a Common Egress Pathway in Multiple Cell Types.

Linde ME, Colquhoun DR, Ubaida Mohien C, Kole T, Aquino V, Cotter R, Edwards N, Hildreth JE, Graham DR.SourceGraduate Program in Immunology, ‡Department of Molecular and Comparative Pathobiology, §Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore , Maryland 21205, United States.
Journal of proteome research.J Proteome Res.2013 May 3;12(5):2045-54. doi: 10.1021/pr300918r. Epub 2013 Mar 29.
HIV-1 incorporates a large array of host proteins into virions. Determining the host protein composition in HIV virions has technical difficulties, including copurification of microvesicles. We developed an alternative purification technique using cholesterol that differentially modulates the densit
PMID 23432411

Analyzing surfactant structures on length and chirality resolved (6,5) single-wall carbon nanotubes by analytical ultracentrifugation.

Fagan JA, Zheng M, Rastogi V, Simpson JR, Khripin CY, Silvera Batista CA, Hight Walker AR.SourceNational Institute of Standards and Technology , Materials Science and Engineering Division, 100 Bureau Drive, Gaithersburg, Maryland 20899, United States.
ACS nano.ACS Nano.2013 Apr 23;7(4):3373-87. doi: 10.1021/nn4002165. Epub 2013 Apr 5.
The structure and density of the bound interfacial surfactant layer and associated hydration shell were investigated using analytical ultracentrifugation for length and chirality purified (6,5) single-wall carbon nanotubes (SWCNTs) in three different bile salt surfactant solutions. The differences i
PMID 23530719

Japanese Journal

Effect of exosome isolation methods on physicochemical properties of exosomes and clearance of exosomes from the blood circulation

European Journal of Pharmaceutics and Biopharmaceutics 98, 1-8, 2016-01
NAID 120005697969

A Comparison of Nephrotoxicity of Contrast Medium in Elderly Patients who Underwent Renal or Peripheral Arterial Vascular Intervention

Internal Medicine 55(1), 9-14, 2016
NAID 130005116791

Relationship of glomerular filtration rate based on serum iodixanol clearance to IRIS staging in cats with chronic kidney disease

Journal of Veterinary Medical Science 77(8), 1033-1035, 2015
NAID 130005094667

Related Pictures

★リンクテーブル★

リンク元	「イオジキサノール」

「イオジキサノール」

Iodixanol
Systematic (IUPAC) name
	5-{N-[3-(N-{3,5-bis[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodophenyl}acetamido)-2-hydroxypropyl]acetamido}-1-N,3-N-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
Clinical data
AHFS/Drugs.com	Multum Consumer Information
Pharmacokinetic data
Protein binding	Negligible
Metabolism	Excreted unchanged
Biological half-life	2.1 hours
Excretion	Renal
Identifiers
CAS Registry Number	92339-11-2
ATC code	V08AB09
PubChem	CID: 3724
DrugBank	DB01249
ChemSpider	3593
UNII	HW8W27HTXX
KEGG	D01474
ChEBI	CHEBI:31705
ChEMBL	CHEMBL1200507
Synonyms	5-[acetyl-[3-[acetyl-[3,5-bis(2,3-dihydroxypropylcarbamoyl)-2,4,6-triiodo-phenyl]amino]-2-hydroxy-propyl]amino]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-benzene-1,3-dicarboxamide
Chemical data
Formula	C35H44I6N6O15
Molecular mass	1550.191
	SMILES Ic1c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c(I)c1N(C(=O)C)CC(O)CN(C(=O)C)c2c(I)c(c(I)c(c2I)C(=O)NCC(O)CO)C(=O)NCC(O)CO ;
	InChI InChI=1S/C35H44I6N6O15/c1-13(52)46(30-26(38)20(32(59)42-3-15(54)9-48)24(36)21(27(30)39)33(60)43-4-16(55)10-49)7-19(58)8-47(14(2)53)31-28(40)22(34(61)44-5-17(56)11-50)25(37)23(29(31)41)35(62)45-6-18(57)12-51/h15-19,48-51,54-58H,3-12H2,1-2H3,(H,42,59)(H,43,60)(H,44,61)(H,45,62) ; Key:NBQNWMBBSKPBAY-UHFFFAOYSA-N ;
(what is this?) (verify)

　　[★]

英: iodixanol
商: ビジパーク

匿名

検索

案内

案内

iodixanol